Updated on 19 August 2013
Iron deficiency is a serious complication of many clinical conditions such as chronic heart failure, gastrointestinal disorders, chronic kidney disease and cancer.
Singapore: Swiss-based Vifor Pharma, a company of the Galenica Group, has entered into an exclusive licensing agreement with Zeria Pharmaceutical for the development and commercialization of Ferinject (ferric carboxymaltose) for the treatment of iron deficiency anemia in Japan.
Under the terms of the agreement, Zeria Pharmaceutical will be responsible for all development and commercialization activities for Ferinject in Japan.
Iron deficiency is a serious complication of many clinical conditions such as chronic heart failure, gastrointestinal disorders, chronic kidney disease and cancer, and it is of particular concern for women and the elderly people in Japan where the incidence can be as high as 25 percent. As many as 18 million people in Japan exhibit signs of anemia mainly due to iron deficiency and would benefit from iron replacement therapies1,2,3,4.
The collaboration with Zeria Pharmaceutical is a significant milestone in the global growth strategy for Ferinject. It builds on a large clinical evidence base and rapidly growing commercial experience worldwide in a variety of therapeutic fields. The strong development and marketing capabilities at Zeria Pharmaceutical are ideally suited to introduce this innovative intravenous iron therapy to Japanese patients and physicians.